Floatz logo

Orlistat

Heart Disorder

University of British ColumbiaSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Heart Disorder cohort.

Asset / SponsorPhaseRating
POTASSIUM
Tufts Medical Center
Phase 3BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB
WARFARIN
Massachusetts General Hospital
Phase 3BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Captopril
Children's Cancer Hospital Egypt 57357
Phase 3B

View all 34 →

Same molecule, other indications

Orlistat is also rated in:

type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
73 / 100
View asset →
polycystic ovary syndromeActive
BB
Indicative · Phase 4
70 / 100
View asset →
binge eating disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →